Thermo Fisher Scientific (TMO) UBS 2026 CEO Call Series summary
Event summary combining transcript, slides, and related documents.
UBS 2026 CEO Call Series summary
19 Nov, 2026Market conditions and outlook
Q3 performance was ahead of expectations; outlook was raised during 2026, with strategy driving growth, share gains and stronger financial results.
End markets became more predictable; pharma and biotech strengthened, biotech funding improved, and academic and government markets stabilized.
End markets are expected to keep strengthening and return to normal long-term growth by 2028.
Split government and bipartisan congressional support for NIH were viewed as constructive; academic spending could return to growth in 2027.
Reshoring commitments remain intact, supported by the logic of producing closer to markets and industry profits.
Pharma, biotech and academic markets
Pharma and biotech grew at a high-single-digit rate in Q3; the recovery is underway, with pharma R&D investment and biotech customer confidence strengthening.
Biotech spending remains weighted toward later-stage development; early research is expected to pick up as companies refill pipelines, with early signs in lab supplies.
AI is adding to pharma and biotech R&D investment expectations through the potential for higher returns on research spending.
Academic and government markets were flat in Q3 and expected to decline slightly for 2026; recovery toward low-single-digit growth is expected over the next couple of years.
China represents 7.5% of revenue; recent low-double-digit growth was led by pharma, biotech and semiconductor demand, and could be an upside over the next couple of years.
Business performance and initiatives
Bioproduction has strong positions in cell culture media, single-use technologies and purification; longer-term growth is expected at high single digits to low double digits, after tougher comparisons in coming quarters.
Biosciences and genetic sciences face softer academic and early biotech markets; improvement is expected as 2027 progresses, with growth strengthening meaningfully.
Analytical Instruments grew mid-single digits in Q3, led by electron microscopy, chromatography and mass spectrometry; the new Orbitrap launched to strong demand.
PreCure, formed with Mayo Clinic, will analyze more than one million biological samples to identify disease signals before symptoms appear.
Pharma services is expected to deliver a strong year; reshoring contracts support U.S. medicine production, while Accelerator Drug Development capabilities help customers bring medicines to market faster.
Clinical research revenue grew mid-single digits; long-term growth is expected at mid- to high-single digits, with authorizations and new wins exceeding revenue.
Clario integration was off to a good start around seven to eight months after closing; technology investment supports an AI-enabled clinical development platform expected to become a high-growth, highly profitable business.
Latest events from Thermo Fisher Scientific
- Q3 organic growth and productivity lifted EPS and FY26 guidance as markets improved.TMO
Q3 2026 - Strong Q2 growth, AI-driven demand, and reshoring trends support a robust multi-year outlook.TMO
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 2026 revenue up 10% to $11.99B, adjusted EPS up 13%, and $1B in stock repurchases.TMO
Q2 2026 - Director nominees elected, auditor ratified, executive pay not approved; strong growth and AI focus.TMO
AGM 2026 - Targets 3–6% organic growth for 2026–2027, fueled by AI, innovation, and accretive M&A.TMO
Investor Day 2026 - Q1 2026 revenue rose 6% to $11.01B, adjusted EPS up 6%, and guidance was raised.TMO
Q1 2026 - Q3 revenue up 5% to $11.12B, adjusted EPS up 10%, with strong innovation and acquisitions.TMO
Q3 2025 - Targets 7–9% organic growth, margin expansion, and share gains through innovation and execution.TMO
Investor Day 2024 - Q2 revenue dipped 1% but EPS grew, and guidance was raised after the Olink acquisition.TMO
Q2 2024